Catalyst
Slingshot members are tracking this event:
KalVista Pharmaceuticals (KALV) Reports KVD001 Phase 2 Clinical Trial Results in Patients with Diabetic Macular Edema
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
KALV |
|
|
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 09, 2019
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Diabetic Macular Edema, Diabetic Retinopathy, Kvd001